Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Boehringer Ingelheim considering acquisitions in the self-medication area in the U.S..

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

BOEHRINGER INGELHEIM LOOKING TO EXPAND SELF-MEDICATION BUSINESS IN U.S. and Japan, the company said. The German-based manufacturer of drugs and medical devices stated that it is considering its options with a number of companies. Boehringer is reportedly in exploratory acquisition talks with at least one U.S. company in the self-medication area.

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

EU Launches Critical Medicines Alliance But Prospect Of Act On Manufacturing Still Uncertain

‘Shocking’ MHRA Performance & Poor Data Transparency Blamed For UK’s Clinical Trial Crisis

Updated COVID-19 Vaccines Should Target New JN.1 Variant, Says EMA

EMA Pilots Partnering With Companies To Gain Efficiencies In Preparing Drug Assessment Reports

See All
UsernamePublicRestriction

Register

PS083885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By